Advertisement
Advertisement
RVMD
Revolution Medicines, Inc. Common Stock
206.97
USDSponsored
+1.82
+0.89%
Aug 10, 16:00 UTC -4
Closed
After-Market
205.90
-1.07
-0.52%
RVMD Earnings Reports
Positive Surprise Ratio
RVMD beat 7 of 27 last estimates.
26%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$6.32M
/-$2.09
Implied change from Q2 26 (Revenue/ EPS)
--
/-31.70%
Implied change from Q3 25 (Revenue/ EPS)
--
/+29.81%
Revolution Medicines, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, RVMD reported earnings of -3.06 USD per share (EPS) for Q2 26, missing the estimate of -2.01 USD, resulting in a -51.69% surprise. Revenue reached --, compared to an expected 16.70 million, with a -100.00% difference. The market reacted with a +0.26% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 14 analysts forecast an EPS of -2.09 USD, with revenue projected to reach 6.32 million USD, implying an decrease of -31.70% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Septerna, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.28
Surprise
+33.26%
Sana Biotechnology, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+12.58%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Passage Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.69
Actual
-$2.44
Surprise
+9.62%
FAQ
What were Revolution Medicines, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Revolution Medicines, Inc. Common Stock reported EPS of -$3.06, missing estimates by -51.69%, and revenue of $0.00, -100% below expectations.
How did the market react to Revolution Medicines, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 0.26%, changed from $197.30 before the earnings release to $197.81 the day after.
When is Revolution Medicines, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Revolution Medicines, Inc. Common Stock's next earnings report?
Based on 14
analysts, Revolution Medicines, Inc. Common Stock is expected to report EPS of -$2.09 and revenue of $6.32M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement